Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system

Satoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, Akihiro Watari, Masuo Kondoh, Kie Yoshida-Tanaka, Hidetoshi Kaburagi, Ken Asada, Tetsuya Nagata, Masahiro Nagahama, Kiyohito Yagi, Takanori Yokota

PII: S0168-3659(18)30267-0
DOI: doi:10.1016/j.jconrel.2018.05.010
Reference: COREL 9292

To appear in: *Journal of Controlled Release*

Received date: 23 October 2017
Revised date: 4 May 2018
Accepted date: 10 May 2018

Please cite this article as: Satoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, Akihiro Watari, Masuo Kondoh, Kie Yoshida-Tanaka, Hidetoshi Kaburagi, Ken Asada, Tetsuya Nagata, Masahiro Nagahama, Kiyohito Yagi, Takanori Yokota , Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:10.1016/j.jconrel.2018.05.010

Angubindin-1 opens the blood–brain barrier *in vivo* for delivery of antisense oligonucleotide to the central nervous system

Satoshi Zeniya[a,b,1], Hiroya Kuwahara[a,b,1], Kaiichi Daizo[a,b], Akihiro Watari[c], Masuo Kondoh[c], Kie Yoshida-Tanaka[a,b], Hidetoshi Kaburagi[d], Ken Asada[a,b], Tetsuya Nagata[a,b], Masahiro Nagahama[e], Kiyohito Yagi[c], and Takanori Yokota[a,b,*] tak-yokota.nuro@tmd.ac.jp

[a]Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

[b]Center for Brain Integration Research, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

[c]Graduate School of Pharmaceutical Sciences, Osaka University, Address: 1-6, Yamada-oka, Suita, Osaka 565-0871, Japan

[d]Department of Orthopaedic and Spinal Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

[e]Department of Microbiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan.

[*]Corresponding author.

Abstract

Within the field of RNA therapeutics, antisense oligonucleotide-based therapeutics are a potentially powerful means of treating intractable diseases. However, if these therapeutics are used for the treatment of neurological disorders, safe yet efficient methods of delivering antisense oligonucleotides across the blood–brain barrier to the central nervous

[1] These authors contributed equally to this work.